title: [Multicenter clinical trial on the efficacy of thrombolytic therapy with urokinase and/or anticoagulant with low molecular weight heparin in acute pulmonary embolism].
abstract: OBJECTIVE
  To evaluate the efficacy of thrombolytic therapy with urokinase and/or anticoagulant with low molecular weight heparin in patients with acute pulmonary embolism.
  
  
  METHODS
  127 patients with documented acute pulmonary embolism were treated with different regimens: thrombolysis combined with anticoagulant therapy in 70 cases, thrombolytic therapy alone in 31 cases and pure anticoagulant therapy in 26 cases.
  
  
  RESULTS
  Dyspnea was the most common symptom (91.3%), then cough (74.0%), chest pain (63.0%) and syncope (21.3%). As compared with pre-treatment in each group, there was significant improvement in respiratory rate, heart rate, partial pressure of oxygen in artery and partial pressure of carbon dioxide in artery. The effective rate of thrombolysis combined with anticoagulant therapy, thrombolytic therapy and anticoagulant therapy were 90.0%, 77.4% and 61.5%, respectively, the total effective rate of thrombolytic therapy was 86.1%. The best efficacy was demonstrated in patients within one week after onset of symptoms. The therapy might be effective for cases with duration longer than two weeks after the onset of symptoms.
  
  
  CONCLUSIONS
  Thrombolytic therapy with urokinase combined with low molecular weight heparin is effective and safe for acute pulmonary embolism.
authors.affiliation: Division of Cardiopulmonary Circulation, Cardiovascular Institute & Fu Wai Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China.
authors.forename: Xiansheng
authors.initials: X
authors.lastname: Cheng
authors.forename: Jianguo
authors.initials: J
authors.lastname: He
authors.forename: Mingzhe
authors.initials: M
authors.lastname: Gao
authors.forename: Guangjin
authors.initials: G
authors.lastname: Chen
authors.forename: Shuhua
authors.initials: S
authors.lastname: Li
authors.forename: Zhonghe
authors.initials: Z
authors.lastname: Zhang
authors.forename: Mingwu
authors.initials: M
authors.lastname: Zhao
authors.forename: Sumin
authors.initials: S
authors.lastname: Zhou
authors.forename: Jiwen
authors.initials: J
authors.lastname: Zhao
authors.forename: Lizhu
authors.initials: L
authors.lastname: Cheng
authors.forename: Zhenxiang
authors.initials: Z
authors.lastname: Zhang
authors.forename: Yulin
authors.initials: Y
authors.lastname: Chen
authors.forename: Changming
authors.initials: C
authors.lastname: Xiong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001158:Arteries / Q000502:physiology; D002245:Carbon Dioxide / Q000502:physiology; D004359:Drug Therapy, Combination; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000502:physiology; D010313:Partial Pressure; D011655:Pulmonary Embolism / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D006495:Heparin, Low-Molecular-Weight; D002245:Carbon Dioxide; D014568:Urokinase-Type Plasminogen Activator; D010100:Oxygen